Twist Bioscience is pricing a common stock offering totaling $300 million at a price of $96 per share, according to multiple reports. One outlet describes the transaction as an equity offering, while another notes it is upsized to $300 million. Both accounts state the per-share price is $96. The sources indicate the company is selling shares to raise new capital, but they do not provide additional details in the provided excerpts such as the number of shares to be issued, the underwriters involved, or the expected closing date. The offering size and pricing terms are the central points of agreement across the coverage. After pricing, the proceeds are expected to be used for general corporate purposes, though the provided summaries do not specify a particular use. Overall, the reporting aligns on the key financial terms: $300 million in total proceeds and a $96 share price.